Liver transplantation is the best treatment option available for end-stage liver disease patients. Though the initial survival of the patient depends on the surgical aspect, survival after transplant depends mainly on immunosuppression. But immunosuppression is a double-edged sword, one sharp end we need to maintain the desired immunological quiescence and the other sharp end is the toxicity of these drugs. Extensive usage of these drugs would lead to long-term morbidity and mortality.
Necessity is the mother of inventions, so there is now enormous interest to devise protocols that will allow us to minimize or completely withdraw immunosuppressants after transplantation. Immunological tolerance of the patient towards the new liver is the main aspect of this immunosuppression withdrawal trial. Tolerance-inducing strategies are being focussed on and among them, the use of regulatory cell…
